U.S. markets closed
  • S&P 500

    3,638.35
    +8.70 (+0.24%)
     
  • Dow 30

    29,910.37
    +37.87 (+0.13%)
     
  • Nasdaq

    12,205.85
    +111.45 (+0.92%)
     
  • Russell 2000

    1,855.27
    +10.25 (+0.56%)
     
  • Crude Oil

    45.52
    -0.01 (-0.02%)
     
  • Gold

    1,790.70
    +2.60 (+0.15%)
     
  • Silver

    22.77
    +0.14 (+0.60%)
     
  • EUR/USD

    1.1956
    +0.0043 (+0.36%)
     
  • 10-Yr Bond

    0.8420
    -0.0360 (-4.10%)
     
  • GBP/USD

    1.3334
    -0.0022 (-0.17%)
     
  • USD/JPY

    104.0850
    -0.1650 (-0.16%)
     
  • BTC-USD

    18,264.86
    +496.80 (+2.80%)
     
  • CMC Crypto 200

    333.27
    -4.23 (-1.25%)
     
  • FTSE 100

    6,367.58
    +4.65 (+0.07%)
     
  • Nikkei 225

    26,644.71
    +107.41 (+0.40%)
     

Recap: Exagen Q3 Earnings

Benzinga Insights
·1 min read

Shares of Exagen (NASDAQ:XGN) were flat in after-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 83.65% year over year to ($0.34), which beat the estimate of ($0.48).

Revenue of $10,775,000 up by 3.22% from the same period last year, which beat the estimate of $8,880,000.

Outlook

Exagen hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: Nov 10, 2020

View more earnings on XGN

Time: 04:30 PM

ET Webcast URL: http://public.viavid.com/player/index.php?id=141944

Technicals

Company's 52-week high was at $29.86

52-week low: $10.29

Price action over last quarter: Up 25.84%

Company Profile

Exagen Diagnostics Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets four products under its Avise brand to provide an accurate, timely and differential diagnosis and to optimize the treatment of ARDs. It processed approximately 9,300 patient specimens for its diagnostic product line, Avise SLE. It markets and sells solutions to community rheumatologists.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.